Company Profile
GT Medical Technologies
Company Overview
ABOUT GT MEDICAL TECHNOLOGIES, INC.
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies to improve the lives of patients with brain tumors. GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. The 3D, resorbable collagen tiles embedded with radiation sources are implanted during the last five minutes of brain tumor resection, providing an immediate, dose-intense treatment to eliminate residual tumor cells. This "one and done" procedure allows patients to receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.
OUR PURPOSE - GT Medical Technologies is dedicated to improving the lives of patients with brain tumors.
OUR OPERATING PRINCIPLES
- Patient/Customer Focus - We are focused on improving the lives of patients with brain tumors by supporting our customers in all that we do.
- Constructive Engagement - We are a team that is committed to the success of our company. We value all opinions; respectfully speak our minds; listen intently; agree to disagree, and commit to our decisions.
- Collaboration - We cooperate within the organization and with our partners in pursuit of improving the lives of patients with brain tumors.
- Consistency - We are a team that behaves consistently to produce predictable positive outcomes and encourage trust.
- Compliance - We abide by industry and regulatory guidelines in operating our business.
- Creativity - We produce innovative solutions that advance our purpose of improving the lives of patients with brain tumors.
- Value - We optimize value for all stakeholders, beginning with the patient and through external relationships, which ultimately results in greater enterprise value.
- Perseverance - We achieve objectives with sustained effort despite difficulties, setbacks, or opposition—doggedly pursuing our purpose.
Notable Accomplishments / Recognition
July 12, 2022 -- For his invention of GammaTile® Therapy used to treat operable brain tumors, David Brachman, M.D. is the 2022 winner of the Mensa Foundation's Copper Black Award for Creative Achievement.
June 29, 2022 - GT Medical Technologies has earned the International Organization for Standardization (ISO) 13485:2016 certification from GMED. The certification demonstrates the company's compliance with medical device quality management system requirements under the Medical Device Single Audit Program (MDSAP). ISO/MDSAP certifications emphasize a key achievement in the global commercial expansion plans for GT Medical Technologies' FDA-cleared GammaTile® Therapy.
May 3, 2022 - GT Medical Technologies, Inc. was named Company of the Year for Health Products & Services in the 2022 American Business Awards. This honor acknowledges GT Medical Technologies' pioneering technology GammaTile® Therapy, FDA-cleared for treating newly diagnosed malignant and recurrent brain tumors.
Oct. 18, 2021 - GT Medical Technologies, Inc. was named a winner of the Innovator of the Year in the small company category at the 2021 Governor's Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13.
May 17, 2021 - GT Medical Technologies was honored by AZ Big Media with a 2021 Healthcare Leadership Award in the Healthcare Innovators of the Year category, which recognizes the best and the brightest in healthcare in Arizona. The company was acclaimed for its breakthrough GammaTile® Therapy that improves the lives of patients with brain tumors and was chosen by the editorial department at AZ Big Media for this award.
March 9, 2020 - GT Medical Technologies named as "Fierce 15" Company of 2019 by FierceMedTech.
August 26, 2019 - The Arizona Bioindustry Association (AZBio) announced that GT Medical Technologies, Inc. (GT MedTech) has been named an AZBio Fast Lane Company and will be honored on October 2, 2019 at the AZBio Awards.
April 11, 2019 - Peter Nakaji, M.D., GT Medical Technologies, Inc. co-founder and director of the Neurosurgery Residency Program at Barrow Neurological Institute in Phoenix, has been selected by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors to receive the 2019 Rosenblum-Mahaley Clinical Research Award. The award recognizes established investigators in neuro-oncology who present the best clinical study in the field and acknowledges innovative approaches that lead to improved patient outcomes and quality of life.
March 15, 2018 - GT Medical Technologies, Inc., is selected as the winner of the MedTech Innovator Accelerator Regional Pitch Competition in San Francisco.
February 22, 2018 - GT Medical Technologies, Inc. is selected as one of six Arizona bioscience firms to receive the Flinn Foundation Entrepreneurship Program.